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Simple Summary: In this work, we aimed to discover unknown genes that are important in the
regulation of other genes. These genes often play an important role during the development of the
embryo. By screening thousands of mice, we found a gene, namely, Nuclear Respiratory Factor 1 (Nrf1),
that controls the switching on and off of other genes. Mice with a defective Nrf1 present lesser levels
of the gene and embryonic delay. When the mutation is in both chains of the DNA, mice are not
born and die in the uterus. Our work unveils a novel, previously unknown functionality of Nrf1 and
provides a new mice model for the study of diseases caused by a defective Nrf1.
Abstract: We have established a genome-wide N-ethyl-N-nitrosourea (ENU) mutagenesis screen to
identify novel genes playing a role in epigenetic regulation in mammals. We hypothesize that the ENU
mutagenesis screen will lead to the discovery of unknown genes responsible of the maintenance of
the epigenetic state as the genes found are modifiers of variegation of the transgene green fluorescent
protein (GFP) expression in erythrocytes, which are named MommeD. Here we report the generation
of a novel mutant mouse line, MommeD46, that carries a new missense mutation producing an
amino acid transversion (L71P) in the dimerization domain of Nuclear Respiratory Factor 1 (Nrf1).
The molecular characterization of the mutation reveals a decrease in the Nrf1 mRNA levels and
a novel role of Nrf1 in the maintenance of the DNA hypomethylation in vivo. The heritability of
the mutation is consistent with paternal imprinting and haploinsufficiency. Homozygous mutants
display embryonic lethality at 14.5 days post-coitum and developmental delay. This work adds a
new epi-regulatory role to Nrf1 and uncovers unknown phenotypical defects of the Nrf1 hypomorph.
The generated mouse line represents a valuable resource for studying NRF1-related diseases.
Keywords: NRF1; Nrf1; ENU mutagenesis; epigenetics; transcription factor; embryonic development;
DNA methylation
1. Introduction
Mutagenesis screens for the identification of modifiers of position-effect variegation
(PEV) in Drosophila melanogaster have been pivotal for the development of the field of
epigenetics [1]. These screens, performed in X-ray irradiated flies, have identified PEV
alleles able to modify the expression of various genes presenting variegated expression,
including the white (w) locus which leads to an easily-identifiable mosaicism of white and
red patches in the eyes [1]. The identified alleles have been classified as dominant enhancers
or suppressors of variegation, namely E(var)s or Su(var)s [2,3], depending on whether they
enhance or suppress heterochromatin-mediated gene silencing. Similarly, mutagenesis
screens have been performed in mammals for the identification of PEV modifiers. For this
purpose, our group has established an N-ethyl-N-nitrosourea (ENU) forward dominant
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mutagenesis screen in transgenic mice (Line3) expressing green fluorescent protein (GFP)
in erythrocytes in a variegated manner [4,5]. The transgene is composed by the human
α1-globin gene promoter and the human α-globin locus enhancer region (HS-40) which is
linked to the human GFP (reporter gene) [5]. Such a construct is expressed in approximately
55% of the erythrocytes of Line3 mice [6]. In this screen, enhancers and suppressors of
variegation are easily identified by flow cytometry with a drop of blood [7,8], and are
denominated as MommeDs (modifiers of murine metastable epialleles, Dominant). In our
laboratory, this screen has successfully identified more than 40 unknown and known genes
playing a role in fundamental epigenetic processes in mammals [4,6–14]. Nearly all these
genes are also required for correct embryonic development [6–8,10,13] and have been linked
to a broad range of syndromes and diseases. For instance, reduced levels of Structural
Maintenance of Chromosomes Flexible Hinge Domain Containing 1 (SMCHD1) have been
associated to the human facioscapulohumeral dystrophy type 2 and cancer [15,16], a loss-
of-function mutation in Wiz has been associated with anxiety-like behavior in mice [14] and
loss of Rearranged L-Myc fusion (RLF) has been shown to cause heart defects in mice [17].
Herein, we report the identification and characterization of a novel mutation in the
Nuclear Respiratory Factor 1 gene (Nrf1). The mice line is named MommeD46. NRF1
is a transcription factor initially found to bind the cytochrome c promoter and activate
transcription [18]. NRF1 regulates respiration, mitochondrial biogenesis and mitochondrial
DNA transcription and replication [19–21]. Consistent with being identified in our muta-
genesis screen, Nrf1 plays a role in the maintenance of DNA hypomethylation, because
the under-functioning Nrf1 induces hypermethylation. Moreover, the novel Nrf1 mutation
is homozygous lethal and presents a characteristic hereditability consistent with paternal
imprinting and haploinsufficiency. This work adds a new epi-regulatory role to Nrf1
and discovers unknown embryonic effects of a novel Nrf1 hypomorph. The generated
mouse line could be used for modeling and studying diseases caused by an underfunction-
ing NRF1.
2. Materials and Methods
2.1. Animals
All animal experiments were performed in accordance with protocols approved by the
Animal Ethics Committee of QIMR Berghofer Medical Research Institute. All the animal
experiments comply with the ARRIVE guidelines. Pups were weaned at three-weeks-old
and bred when males and females were eight and six-weeks-old, respectively. The ENU
screen was performed in FVB/NJ inbred transgenic mice, namely Line3, homozygous for
the green fluorescence protein (GFP) transgene under the control of the α-globin promoter,
as previously described [4]. MommeD46 was maintained in this mice line and crossed for at
least five generations with wild-type FVB/NJ mice, down from the mutant founder. Line3C
mice were used for the linkage analysis (Figure 1a). Line3C was obtained by crossing Line3
with mice of strand C57BL/6J for ten generations and selecting for the offspring carrying
the GFP transgene by flow cytometry. C57BL/6J mice were purchased from the Animal
Resources Centre (Perth, WA, Australia). Sperm of MommeD46 is cryopreserved at the
Australian Phenome Bank at the Australian National University (2601 ACT, Australia).
2.2. Embryo Dissections
Heterozygous MommeD46 mice were crossed and females were daily monitored for
vaginal plugs. A vaginal plug was counted as 0.5 days post-coitum (dpc). Pregnant females
were sacrificed by CO2 inhalation, dissected and embryos isolated and visualized under a
binocular dissecting microscope.
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Figure 1. MommeD46 is an enhancer of variegation. (a) Schematic representation of the ENU muta-
genesis gene discovery pipeline. (b) Table indicating the average percentage of GFP positive eryth-
rocytes ± standard deviation (SD) for Nrf1+/+ and Nrf1MommeD46/+. Nrf1MommeD46/MommeD46 were not viable 
at weaning. (c) Graph of the GFP fluorescence profile obtained by flow cytometry from a drop of 
blood of Nrf1+/+ (wild-type) and Nrf1MommeD46/+ (heterozygote). Statistical significance was determined 
by two-tailed Student’s t-test, **** indicates p < 0.00005. 
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under a binocular dissecting microscope. 
2.2.1. Determination of GFP Expression in Erythrocytes 
A tiny cut in the tail tip was performed in manually strained (three-weeks-old) mice 
to extract a drop of blood of three-weeks-old mice to be then dissolved in Osmosol buffer 
and analyzed using the benchtop flow cytometer Guava easyCyte HT (Merck/Millipore, 
Darmstadt, Germany). A gating was set to exclude 99.9% of erythrocytes not expressing 
the GFP. 
2.3. Linkage Analysis by SNP Chip 
DNA from tail tips from 15 mice phenotypically expressing GFP in 55% of the eryth-
rocytes (wild-type) and 15 expressing lower GFP percentages (MommeD46) from the back-
cross between heterozygous MommeD46 with Line3 background (FVB/NJ strain) and 
Figure 1. MommeD46 is an enhancer of variegation. (a) Schematic representation of the ENU mutagenesis gene discovery
pipeline. (b) Table indicating the average percentage of GFP positive erythrocytes ± standard deviation (SD) for Nrf1+/+
and Nrf1MommeD46/+. Nrf1MommeD46/MommeD46 were not viable at weaning. (c) Graph of the GFP fluorescence profile obtained
by flow cytometry from a drop of blood of Nrf1+/+ (wild-type) and Nrf1MommeD46/+ (heterozygote). Statistical significance
was determined by two-tailed Student’s t-test, **** indicates p < 0.00005.
Determination of GFP Expression in Erythrocytes
A tiny cut in the tail tip was performed in manually strained (three-weeks-old) mice
to extract a drop of blood of three-weeks-old mice to be then dissolved in Osmosol buffer
and nalyzed using the benchtop flow cytometer Guava easyCyte HT (Merck/Millipore,
Darmstadt, Germany). A gating was set to xclude 99.9% of erythrocytes not expressing
the GFP.
2.3. Linkage Analysis by SNP Chip
DNA from tail tips from 15 mice phenotypically expressing GFP in 55% of the ery-
throcytes (wild-type) and 15 expressing lower GFP percentages (MommeD46) from the
backcross between heterozygous MommeD46 with Line3 background (FVB/NJ strain) and
Line3C (C57BL/6J strain) mice were included in the linkage analysis (Figure 1a). Mice were
at least three-weeks-old. The Mouse Medium Density Linkage Panel from Illumina (San
Diego, CA, USA) was used for single nucleotide polymorphism (SNP) genotyping. The
panel contains 766 measurable differential SNPs between C57BL/6J and FVB/NJ strains.
Wild-type mice for the mutation should only have C57BL/6J-specific SNPs in the linked
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region while heterozygous MommeD46 mice can have both C57BL/6J and FVB/NJ-specific
SNPs. SNP Chip was performed according to Illumina instructions and SNP calling was
carried out using the Genotyping module of the GenomeStudio v1.1 software (Illumina).
Only call rates higher than 95 were accepted. Logarithm of odds (LOD) scores across the
entire mouse genome were calculated and linked intervals identified (LOD scores > 2,
Figures 1a and 2). Further fine mapping using additional SNP markers (Figure S1) was
performed to reduce the linked interval.
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2.5. Methylation Analysis in the Transgene HS-40 Enhancer 
DNA samples from three wild-type, three heterozygous and three homozygous 
MommeD46 9.5 dpc embryos were converted with bisulfite using the EpiTect Bisulfite Kit 
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Figure 2. The point mutation in the MommeD46 is localized in Chromosome 6. (a) Manhattan plot showing the linked
intervals identified by SNP Chip in MommeD46. The y-axis represents the logarithm of the odds (LOD) score and the
x-axis represents the Chr number. (b) Scheme of the fine mapping performed in the linked interval identified by SNP
Chip in Chr 6 comprising a genomic region ranging from 4.5 Mb to 127.8 Mb. The numbers indicate the number of mice
having a heterozygous or wild-type genotype in the genomic regions indicated. The blue boxes represent the existence of
FVB/NJ-specific SNPs and the yellow boxes the existence of C57BL/6J-specific SNPs at the given markers.
2.4. Whole Exome Sequencing
Whole exome sequencing for the identification of the underlying mutation in MommeD46
was carried out as previously described [7].
2.5. Methylation Analysis in the Transgene HS-40 Enhancer
DNA samples from three wild-type, three heterozygous and three homozygous
MommeD46 9.5 dpc embryos were converted with bisulfite using the EpiTect Bisulfite
Kit (Qiagen, Doncaster, VIC, Australia) in accordance with the manufacturer’s instruc-
tions. Bisulfite-converted DNA was amplified (first PCR) using specific oligon cleotides
(Integrated DNA T chnologi s, IA, USA) for the HS-40 nhanc r region, as follows: 5′-
AAAATAA ATTTTTGGATTGTTATTATTATAA-3′ (Forward 1), 5′-ATATTTGTAATTTTA-
GTATTTTGGGAGGTT-3′ (Forward 2) and 5′-AATCTCTACTCACTACAAACTCCATCTC-
3′ (Reverse) with the following cycling conditions: one cycle at 94 ◦C for 2 min; 35 cycles at
94 ◦C for 30 s, 60 ◦C for 30 s, 72 ◦C for 45 s; one cycle at 72 ◦C for 6 min. Next, a semi-nested
PCR was performed with the first PCR product using the oligonucleotides Forward 2 and
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Reverse. The product was then ligated into a pGEM®-T Vector (Promega, Madison, WI,
USA) as per Promega instructions. DH5α competent E. coli were transformed using the
heat shock method and plated in LB agar plates containing ampicillin, x-gal and IPTG. Posi-
tive colonies (white) were picked and DNA was amplified to determine transgene insertion
using the following oligonucleotides: 5′-ATTTAGGTGACACTATAG-3′ (Forward, SP6) and
5′-TAATACGACTCACTATAGGG-3′ (Reverse, T7) and PCR conditions according to the
MangoTaq DNA polymerase protocol (Bioline Reagents Limited, London, UK). Plasmid
DNA from positive colonies was then extracted with Qiagen Miniprep Kit (Germantown,
MD, USA) and sequenced. The BIQ Analyser software was used to determine the quality
of the conversion and for the analysis. Sequences with <98% of conversion rate and <80%
of sequence matching as well as identical clones were excluded from the analysis. White
and dark circles-containing diagrams, obtained from introducing the BIQ results’matrix to
the software freshteapot, were used to represent the unmethylated and methylated CpG
sites in the HS-40 enhancer, respectively.
2.6. Genotyping
Genotyping of MommeD46 was performed by Sanger sequencing or by restriction
enzyme digestion followed by gel electrophoresis. For both genotyping methods, DNA
from tail tips (at least three-weeks-old) and embryos was extracted using a saturated salt
solution containing 50 mM Tris pH 6.8, 20 mM EDTA pH 8, 2% SDS and 6.25 µg/mL
proteinase K. DNA was precipitated with isopropanol and washed with 75% and 100%
ethanol. DNA pellets were air dried and treated with 200 µL of RnaseA (10 mg/mL).
Sanger sequencing was performed for 9.5 dpc embryos genotyping (Figure 3b). Wild-type,
heterozygous and homozygous MommeD46 embryos (Figure 3b) were homogenized. DNA
was isolated and a genomic region of 321 base pairs (bp) covering the causative mutation in
Nrf1 was amplified by PCR using the oligonucleotides 5′-GGCTCAGCCAGTGTTTTCTTA-
3′ (forward) and 5′-TTTGATCCCCAGCAGTGAA-3′ (reverse). The PCR product was then
sequenced using the BigDye Terminator Sequencing Kit (Applied Biosystems, Foster City,
CA, USA) and the previous forward oligonucleotide. The restriction enzyme digestion
was performed for both adult and embryo genotyping. To do so, the same obtained above
PCR product was subjected to digestion with HpaII (New England BioLabs, Ipswich, MA,
USA). In wild-type MommeD46 the enzyme did not cut, in heterozygous MommeD46 the
enzyme only cut one DNA strand, producing fragments of 321 bp, 173 bp and 148 bp, and
in homozygous MommeD46 the enzyme cut both DNA strands, producing fragments of
173 bp and 148 bp.
2.7. Determination of Nrf1 mRNA Levels by Quantitative Real-Time PCR
The determination of Nrf1 mRNA levels was performed in three wild-type, three
heterozygous and three homozygous MommeD46 of at least three weeks of age, following a
three-step process which included RNA isolation, cDNA conversion and quantitative real-
time (qRT)-PCR. For RNA isolation, 9.5 dpc embryos were mechanically homogenized and
treated with Trizol® (Qiagen, Doncaster, VIC, Australia) and chloroform. RNA was precipi-
tated with isopropanol and high salt solution (0.8 M NaCitrate and 1.2 M NaCl). RNA was
washed with 75% ethanol, air dried and dissolved in DEPC water. RNA was converted into
cDNA using SuperScriptIII reverse transcriptase and random hexamer primers (Invitrogen,
Carlsbad, CA, USA). For the qRT-PCR, the forward oligonucleotide for Nrf1 was designed at
the boundary of the first exon and the second exon (5′-TGAGGTCGAATGGTATGTGGT-3′),
and the reverse oligonucleotide 78 bp downstream (5′-ACACCCATGTTCATAGCAGCA-
3′), leaving a product of 121 bp. The DNA amplification was performed using the Platinum
SYBR Green qPCR Super Mix—UDG (Invitrogen, Carlsbad, CA, USA). The PCR was
run in the Viia7 (Applied Biosystems, Mulgrave, VIC, Australia) and analyzed using the
Viia7 software. Hprt was used as housekeeping gene, using the qRT-PCR oligonucleotides
5′-GGCCAGACTTTGTTGGATTT-3′ (forward) and 5′-ACTGGCAACATCAACAGGACT-
3′ (reverse).
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2.8. Determination of Nrf1 Protein Levels by Western Blot
Whole-protein extracts were prepared from three wild-type, three heterozygous and
three homozygous MommeD46 9.5 dpc embryos. Embryo tissue was mechanically homog-
enized and lysed with lysis buffer containing urea 8 M, 1% sodium dodecyl sulfate, 10%
glycerol, 0.5 mM dithiothreitol and 10 mM Tris pH 6.8, complemented with the serine
protease inhibitor phenylmethylsulfonyl fluoride and half tablet of the protease inhibitor
cocktail cOmplete® from Roche (Swedesboro, NJ, USA) for 5 mL of lysis buffer. Next, sam-
ples were sonicated and quantified using the Pierce BCA Protein Assay Kit (ThermoFisher
Scientific Australia Pty Ltd., Scoresby, VIC, Australia). Equal amounts of protein (30 µg)
ere loaded in a Mini-Protean precast 7.5% polyacrylamide gel from Bio- ad (Hercules,
CA, US ) and run at 100 V. Proteins w re transferred into PVDF embr nes following
the wet transfer protocol, overnight at 4 ◦C at 20 V. Membranes were blocked with 5%
of skim milk and 1% BSA in PBS-T. The anti-Nrf1 antibody from Novus Biologicals (Lit-
tleton, CO, USA) was incubated in the same solution overnight at 4 ◦C, 1:1000 dilution.
A goat anti-rabbit secondary antibody conjugated to horseradish peroxidase (HRP) from
DAKO, 1:5000 dilution in PBS-T, (Santa Clara, CA, USA) was added for one hour at room
temperature. Clarity Western ECL substrate (Bio-Rad) was added in the membrane and
the chemiluminescence signal was captured with the MF Chemi-Bis (DNR Bio-imaging
systems). The γ-Tubulin antibody from Sigma-Aldrich (St Louis, MO, USA), 1:1000 dilution,
was used as loading control.
2.9. Statistical Analysis
All the experiments were done in at least three biological replicates. Normality of data
was assessed by Saphiro–Wilk or Kolmogorov–Smirnov tests, depending on the sample
size. When the data were satisfied with normality assumption, statistical significance
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between mean differences of the groups was assessed by two-tailed Student’s t-test or
one-way ANOVA and p < 0.05 was considered significant. Otherwise, the non-parametric
Mann–Whitney U test was applied and p < 0.05 was considered significant. Chi–Square test
(χ2) or Fisher’s exact test (F) were used to compare the observed proportion of genotypes
with the expected Mendelian ratios when the number of events in a cell was ≥5 or <5,
respectively, and a p value < 0.05 was deemed as significant. Levene’s test or F-test of
equality of variances was used to determine variance differences between wild-type and
heterozygous distributions, holding significance when p < 0.05. In this figure, two-way
ANOVA was also employed. All analyses were performed using the software IBM SPSS
Statistics version 24.0 (Chicago, IL, USA).
3. Results
3.1. MommeD46 Is an Enhancer of Variegation
The causative mutation in MommeD46 induces a change in the GFP expression in
erythrocytes. Wild-type MommeD46 mice express the GFP in approximately 55% of red
blood cells (Figure 1b), as previously shown for Line3 mice [7]. Heterozygous MommeD46
mutants present 44 ± 5% of GFP-expressing erythrocytes, which is significantly less
(p = 2.15 × 10−28) than the percentage observed in their wild-type counterparts (53 ± 4%).
Figure 1c shows the flow cytometry GFP profiles of wild-type and heterozygous mutant
MommeD46. Mutant mice show a lesser count. Therefore, MommeD46 is an enhancer of
variegation.
3.2. MommeD46 Carries a Point Mutation in the Nrf1 Gene
To elucidate the underlying mutation in MommeD46, we followed different strategies.
First, we performed SNP Chip to determine the linked genomic interval where the mutation
was located. We identified two linked regions with LOD score of 2 or higher in Chromosome
(Chr) 6 and Chr 15 (Figure 2a). As the highest LOD score was in Chr 6, we narrowed down
the linked interval in that Chr, comprising a region of 123.3 Mb, from the genomic location
4.5 Mb to 127.8 Mb (Figure S1). We exploited nine differential SNP markers between
FVB/NJ and C57BL/6J at 4.5, 21.9, 34.7, 38.1, 41.4, 48.7, 75.5, 107.8, and 127.8 Mb. We
found a number of supporting genotypically heterozygous mice, and thus, with C57BL/6J-
specific SNPs, concentrated at 21.9 and 34.7 Mb. At the same locations, we also found
genotypically wild-type mice (with FVB/NJ-specific SNPs) (Figure 2b). This observation
indicated that the underlying mutation in MommeD46 was located somewhere between
21.9 and 34.7 Mb. Later, we performed exome deep sequencing and we identified the
causative mutation to be a missense mutation at the end of the third exon of Nrf1 (Chr
6:30,040,135; USC Genome Browser) (Figure S2). This was confirmed by Sanger sequencing
in 9.5 dpc embryos (Figure 3b). The mutation is a T > C substitution that induces a Leucine
(L) > Proline (P) change at position 71 of the amino acid sequence of Nrf1, located before
the predicted Nrf1 DNA binding domain. The affected amino acid is conserved between
species (Figure 3a). The point mutation in Nrf1 causes a decrease in the Nrf1 mRNA levels
as seen by qRT-PCR. In particular, Nrf1MommeD46/+ and Nrf1MommeD46/MommeD46 9.5 dpc
embryos showed a 15% (p = 0.014) and a 44% reduction (p = 0.0004) in Nrf1 mRNA levels,
respectively, compared to Nrf1+/+ (Figure 3c). In contrast, the mutation did not induce a
noticeable change in the Nrf1 protein levels as observed by Western blot (Figure 3d). In
addition, the band quantification of the Western Blot did not show significant differences
of band intensity between the groups when normalized to γ-Tubulin (Figure S3).
3.3. Nrf1 Mutants Display Enhanced DNA Methylation
To further prove a role of Nrf1 as epigenetic regulator in mammals, we performed
bisulfite sequencing of the HS-40 enhancer region of the GFP transgene in wild-type,
heterozygous and homozygous MommeD46 9.5 dpc embryos. We observed that Nrf1+/+
embryos presented 57% of the CpG islands methylated. This percentage increased up
to 66% in Nrf1MommeD46/+ embryos, and up to 71% in Nrf1MommeD46/MommeD46 embryos
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(p = 0.049) (Figure 4). This result suggests that Nrf1 is involved in DNA methylation and a
functional Nrf1 is essential to maintain a hypomethylated state, which is consistent with
the fact that Nrf1 is an enhancer of variegation.
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3.4. The Observed Hereditability of the Nrf1 Suggests Paternal Imprinting and Haploinsufficiency,
and Normal Nrf1 Is Required for Normal Embryonic Development
Herein, we wanted to determine whether the newly discovered mutation in Nrf1 was
responsible for any phenotypic change or defects in mice. To do so, we performed different
intercrosses between adult Nrf1MommeD46/+ mice. We observed proportions of Nrf1+/+,
Nrf1MommeD46/+ and Nrf1Momm D46/MommeD46 to be significantly different than that expected
by Mendel at weaning (p < 0.001) (Figure 5a). Interestingly, neither homozygous mice were
observed at weaning nor at the embryonic stage of 14.5 dpc indicating an earlier embryonic
lethality of the mutation in homozygosis. In the earlier embryonic stages of 8.5, 9.5 and
10.5 dpc, homozygous embryos were observed at decreased ratios than expected (not
significant). When further analyzing the homozygous embryos, we detected the presence
of empty decidua in some of them, all presumably being Nrf1MommeD46/MommeD46, while the
rest resembled embryos (Figure 5b). However, some of them looked abnormal. Male and
female heterozygous mice showed similar fertility, producing an average of 7.9 ± 2.1 pups
per litter when the heterozygous progenitor was a male, and 7.7 ± 2.5 pups when the
heterozygous progenitor was a female. As expected, the heterozygous intercross produced
less pups per litter, specifically 6.8 ± 1.3 (Figure 5c). To determine any possible progenitor
effect in the hereditability of the mutation, we genotyped the offspring of two types of
intercrosses: a heterozygous mutant male crossed with a wild-type female, and a wild-type
male crossed with a heterozygous mutant female. The expected Mendelian proportions
for both intercrosses were 50% wild-type and 50% heterozygous mutants. However, we
observed different proportions in both intercrosses, with the ratios significantly different
than expected (p < 0.001) for the intercross including a female wild-type. Moreover, the
percentage of wild-type pups obtained from the intercross containing the female wild-type
was significantly greater (75%) than the percentage obtained from the intercross having
the male wild-type (62%) (p < 0.020) (Figure 5d). Altogether, these results suggest an
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accentuated maternal hereditability and some degree of haploinsufficiency of the described
mutation in Nrf1 which is further discussed in the next section. Finally, to ascertain any
possible embryonic or adult defects caused by the mutation in Nrf1, we determined the body
weights of Nrf1+/+ and Nrf1MommeD46/+ mice at weaning and explored the morphology
of Nrf1+/+, Nrf1MommeD46/+ and Nrf1MommeD46/MommeD46 embryos at different embryonic
stages. As seen in Figure 5e, heterozygous mutant mice weighed less than their wild-type
counterparts in both sexes (not significant), with significantly different variances found
in males (Levene’s F-test, p < 0.05). When examining the embryos at 8.5 and 9.5 dpc, we
observed that homozygous mutant embryos were clearly smaller and less developed than
the wild-type or heterozygous mutants (Figure 5f). However, no differences were detected
between wild-type and heterozygous mutant embryos. This observation highlights the
importance of Nrf1 for correct embryonic development.
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after birth obtained from the heterozygous intercross. The respective percentages are between parentheses. (b) Table
showing the number of normal and abnormal (empty decidua) offspring at 8.5 dpc, 9.5 dpc, 10.5 dpc and 14.5 dpc obtained
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4. Discussion
By deploying a forward dominant ENU mutagenesis screen in mice, we have discov-
ered a novel missense mutation in Nrf1 capable of altering the epigenetic state. Additional
mutations were found in the link obtained by SNP-Chip but outside the fine mapped
interval (Figure S4), which reassured us that the mutation in Nrf1 was causative of the
phenotype. Nrf1 is an enhancer of variegation as seen by the decrease in the percentage of
GFP positive erythrocytes in heterozygous mutant mice. The exonic mutation in Nrf1 is
responsible for the amino acid (aa) change L > P at the position 71 of the Nrf1 protein (total
length: 503 aas) and is located in the aa region responsible for Nrf1 dimerization. This
region ranges between 1 and 78 aas as the previously generated 1-to-78-deletion mutant
has been shown to be entirely monomeric [22]. This same mutant also binds DNA less
robustly compared to the wild-type protein [22], consistent with a possible overlap with
the Nrf1 DNA binding domain, predicted to be between 79 and 172 in the chicken Nrf1 [23].
This suggests that the 71L > P substitution of MommeD46 could perturb both the homod-
imerization and DNA binding ability of Nrf1. Nrf1MommeD46/+ and Nrf1MommeD46/MommeD46
embryos show substantial reduction in the Nrf1 mRNA levels indicating that the mutation
could affect mRNA synthesis and processing. In contrast, Nrf1 protein levels do not seem
to be altered in the mutant embryos. This could be due to increases in the half-life of the
mutated Nrf1 protein or an increase in the Nrf1MommeD46 mRNA translation, processes
that have been reviewed in Liu et al. [24]. As for studies with Nrf1, Dhar et al. found a
drastic reduction in Nrf1 mRNA levels by qRT-PCR accompanied with a not so accentuated
decrease in protein levels by Western blot in murine neuroblastoma cells [25].
We are the first to demonstrate a role of Nrf1 in maintaining DNA hypomethylation
in vivo as seen by the significant hypermethylation of the α-globin HS-40 enhancer region
observed in Nrf1MommeD46/+ and Nrf1MommeD46/MommeD46 embryos in comparison with wild-
type embryos. Interestingly, only this present MommeD46 and the previously published
MommeD28 (Rlf null mutant) [7] show hypermethylation in the HS-40 enhancer. This is
consistent with the decreased expression of the GFP transgene. Although the preference
of NRF1 to bind un-methylated regions [26,27] and methylated sequences [28] has been
studied in depth, little is known about the role of Nrf1 in directly controlling DNA methy-
lation. In this line, one study has found that Nrf1 transcriptionally activates Euchromatic
histone methyltransferase 1 (EHMT1) during in vitro meiosis, and that its DNA binding
ability is negatively regulated by CDK2-mediated phosphorylation [29]. However, the
authors did not assess DNA methylation changes. In another work, the authors did not find
changes in DNA methylation in the gene promoters of the six Nrf1 target genes analyzed
in CD9+ spermatogonia from Nrf1 germ cell-conditional knockout (Nrf1f/f) mice [27]. In
contrast, in our study, Nrf1 was isolated from a genome-wide genetic screen in search of
epigenetic modifiers and we found methylation changes in the HS-40 enhancer in mutants
with dysfunctional Nrf1. Besides all this, it could be that NRF1 indirectly maintains DNA
hypomethylation. The mutation L71P in Nrf1 could reduce the ability of Nrf1 to bind the
DNA, such that Nrf1 is then unable to protect the CpG sites from methylation, leading to a
methylation gain as previously described [26].
According to our embryonic and adult examinations of MommeD46, Nrf1MommeD46/MommeD46
mice are not viable at birth and die before 14.5 dpc. Also, the offspring of the heterozygous
intercross present significantly altered Mendelian ratios at weaning. Similarly, the Nrf1 full
knockout has shown to be embryonic lethal between 3.5 and 6.5 dpc [30]. Regarding mice
fertility, our mutation in Nrf1 does not seem to affect fertility as seen by the similar average
litter sizes obtained from the cross Nrf1+/+ × Nrf1MommeD46/+ for both progenitor genders.
However, in the literature, conditional ablation of Nrf1 in gonocytes has been shown to lead
to infertility in male mice [27]. This contrasting evidence could be due to the subtle nonob-
vious effect that our mutation has on fertility. We observed that the wild-type Nrf1 allele is
significantly more present than expected in the offspring when the progenitor is a wild-type
female rather than when it is a wild-type male (75% versus 62%). This could be explained
by paternal imprinting of the mutated allele in the mating ♀Nrf1+/+ × ♂Nrf1MommeD46/+,
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by maternal imprinting of the mutated allele in the mating ♀Nrf1MommeD46/+ × ♂Nrf1+/+,
by haploinsufficiency or by the existence of an additional ENU mutation having a cis- or
trans-acting effect on the wild-type or the mutated allele. Maternal imprinting or inhibitory
cis-/trans-acting effects on the mutated allele does not occur because the proportion of
Nrf1MommeD46/+ progeny from the mating ♀Nrf1MommeD46/+ × ♂Nrf1+/+ is not significantly
different from the expected Mendelian ratios, 38% versus 50%. In contrast, the possibility
of activating cis- or trans-activating effects on the wildtype allele due to another ENU
mutation cannot be ruled out, but, at the same time, is very difficult to prove. Regarding
Nrf1 inheritance, the literature shows that there is no maternal inheritance of Nrf1 gene
products as wild-type embryo eggs (Nrf1+) from the Nrf1null/+ heterozygous intercross
were seen at the stage before the first meiotic division [30]. Regarding paternal imprinting,
NRF1 has previously been shown to positively regulate the small nuclear ribonucleoprotein
polypeptide N (SNRPN) locus which is associated with the imprinting center that regulates
the Prader–Willi syndrome domain (PWS-IC), suggesting a relevant contribution of NRF1
in PWS-IC activity [31,32]. In other words, NRF1 orchestrates the characteristic loss of
expression of the paternally-inherited allele of an imprinted gene cluster, that includes
SNRPN, in the PWS. This suggests that the mutation in MommeD46, which affects the
dimerization and DNA binding capabilities of Nrf1, could generate imprinting defects and
be responsible for the increase in the expression of the maternal wild-type allele observed.
Another possibility that could explain the greater presence of the wild-type allele in the
offspring when the progenitor is a wild-type female is the haploinsufficiency caused by
the mutated Nrf1 allele in the heterozygous mice. The early lethality of the homozygous
mutants supports this notion.
Regarding the effects of the mutation in embryos and adult phenotypes, we observed
a decrease in size and developmental delay in 9.5 and 10.5 Nrf1MommeD46/MommeD46 embryos
compared to wild-type embryos. Moreover, both male and female Nrf1MommeD46/+ mice
display a slight decrease in body weight compared to wild-type mice at weaning, with
significantly different variances in males. Similarly, a previous study demonstrated de-
fective development in vitro of all Nrf1-null and some Nrf1 heterozygous blastocysts as
opposed to their wild-type counterparts [30]. In mice, Nrf1 is highly expressed in thymo-
cytes, B-cells and retina, and in humans, in natural killer cells, T cells and skeletal muscle.
Consistent with that, retinal progenitor cell and postmitotic rod photoreceptor cell-specific
Nrf1 conditional knockout mice exhibit rod photoreceptor cell degeneration as a result of
mitochondrial impairment [33]. In addition, Drosophila erect wing (ewg) (Nrf1 homologue)
mutants show aberrant axonal projection and absent or reduced indirect flight muscles [34],
and zebrafish nrf (Nrf1 homologue) mutants exhibit loss of retinal photoreceptors and
reduced brain size [35]. Also in the neural context, reduced transcriptional activity of NRF1
has been associated with fragile X mental retardation syndrome [36] and with GABA-
associated neuronal disorders [37], and functional NRF1 has been shown to be necessary
for neurite outgrowth of human neuroblastoma cells [38,39]. Other non-neuronal roles
attributed to NRF1 are the regulation of oncogenesis [40–43], stem cell aging [44], telomere
transcription [45] and oxidative stress protection and lipid homeostasis in the liver; liver-
specific Nrf1 conditional knockout mice develop steatohepatitis and spontaneous liver
cancer [43]. In addition, low levels of (mRNA) Nrf1 have been observed in Cystathionine
β synthase (CBS) heterozygous-null mice modeling hyperhomocysteinemia, a syndrome
characterized by skeletal muscle weakness and fatigability [46]. However, it remains un-
known whether Nrf1 is a causative factor or a consequence of the disease. Interestingly,
CBS+/−mice exhibit significant weight loss [47], and homocysteine treatment, as a way to
model the disease in vitro, increases the expression of DNA methyltransferase (DNMT)3a
and DNMT3b and consequent global methylation levels in muscle C2C12 cells [46], which
is in agreement with our findings of Nrf1 controlling the epigenetic state and the decrease
in body weight observed in Nrf1MommeD46/+ mice. Alternatively, given that Nrf1 controls
muscle energy production [48], it could be that the decrease in body weight in the heterozy-
gous Nrf1 mutants is due to the reduction in muscle function and subsequent muscle mass.
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Further investigations will be undertaken to unravel other phenotypic traits or defects
caused by the 71L > P substitution in Nrf1.
5. Conclusions
By using a genome-wide mutagenesis screen, we have identified Nrf1 acting as a
controller of the epigenetic landscape in mammals, through the maintenance of DNA hy-
pomethylation in vivo. This novel MommeD46 causes a reduction in the Nrf1 mRNA levels
and severe embryonic developmental defects. Additionally, we noted a peculiar hereditabil-
ity of the mutation which is consistent with a paternal imprinting of the Nrf1MommeD46 allele
and haploinsufficiency. Our study unveils an important new epi-role of NRF1 in addition
to its extensive transcriptional regulation throughout the animal life. Furthermore, the
variant mouse produced in our laboratory could be used to model or elucidate unknown
syndromes driven by a reduced function of NRF1.
Supplementary Materials: The following are available online at https://www.mdpi.com/article/
10.3390/ani11072103/s1, Figure S1: fine mapping of MommeD46, Figure S2: exome sequencing in
MommeD46, Figure S3: Full Western Blot images and band quantification corresponding to Figure 3d.
Full Western Blot images of (a) Nrf1 and (b) γ-Tubulin, Figure S4: Deep genome sequencing of the
linked interval in MommeD46.
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